CoChat

Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial

Open access
Sharma, Abhinav, Ambrosy, Andrew P., DeVore, Adam D., Margulies, Kenneth B., McNulty, Steven E., Mentz, Robert J., Hernandez, Adrian F., Michael Felker, Gary, Cooper, Lauren B., Lala, Anuradha, Vader, Justin, Groake, John D., Borlaug, Barry A., Velazquez, Eric J. · 2018 · ESC Heart Failure
Cited by 45

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. Methods and results: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’ analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a significant weight reduction [liraglutide −1.00 lbs vs. placebo 2.00 lbs; treatment difference −4.10 lbs; 95% confidence interval (CI) −7.94, −0.25; P = 0.0367; percentage treatment difference −2.07%, 95% CI −3.86, −0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference −33.1 mg/dL; 95% CI −60.7, −5.6; P = 0.019). Conclusions: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ehf2.12334

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 15

  1. Horwich, 2011, Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure, Am J Cardiol, 108, 1754, 10.1016/j.amjcard.2011.07.051 · DOI · Paper page
  2. Joyce, 2016, Prevalence, profile, and prognosis of severe obesity in contemporary hospitalized heart failure trial populations, JACC Heart Fail, 4, 923, 10.1016/j.jchf.2016.09.013 · DOI · Paper page
  3. Margulies, 2014, GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study, Circ Heart Fail, 7, 673, 10.1161/CIRCHEARTFAILURE.114.000346 · DOI · Paper page
  4. Lala, 2015, Relief and recurrence of congestion during and after hospitalization for acute heart failure, Circ Heart Fail, 8, 741, 10.1161/CIRCHEARTFAILURE.114.001957 · DOI · Paper page
  5. Cefalu, 2015, Standards of medical care in diabetes, Diabetes Care, 38, 1177, 10.2337/dc15-0875 · DOI
  6. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019 · DOI · Paper page
  7. Sharma, 2017, A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure, Eur J Heart Fail, 19, 1310, 10.1002/ejhf.912 · DOI
  8. Sharma, 2016, Heart failure event definitions in drug trials in patients with type 2 diabetes, Lancet Diabetes Endocrinol, 4, 294, 10.1016/S2213-8587(16)00049-8 · DOI
  9. Carbone, 2016, Lack of benefit for liraglutide in heart failure, JAMA, 316, 2429, 10.1001/jama.2016.15387 · DOI
  10. Margulies, 2016, Lack of benefit for liraglutide in heart failure—reply, JAMA, 316, 2429, 10.1001/jama.2016.15394 · DOI
  11. Rossignol, 2015, Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials, Eur J Heart Fail, 17, 424, 10.1002/ejhf.240 · DOI · Paper page
  12. Wohlfahrt, 2014, Impact of general and central adiposity on ventricular-arterial aging in women and men, JACC Heart Fail, 2, 489, 10.1016/j.jchf.2014.03.014 · DOI · Paper page
  13. Borlaug, 2013, Longitudinal changes in left ventricular stiffness: a community-based study, Circ Heart Fail, 6, 944, 10.1161/CIRCHEARTFAILURE.113.000383 · DOI · Paper page
  14. Zamora, 2016, No benefit from the obesity paradox for diabetic patients with heart failure, Eur J Heart Fail, 18, 851, 10.1002/ejhf.576 · DOI
  15. Kamiya, 2016, Complementary role of arm circumference to body mass index in risk stratification in heart failure, JACC Heart Fail, 4, 265, 10.1016/j.jchf.2015.11.010 · DOI

Cited by

See all 45

Metadata

Authors
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., Vader, J., Groake, J. D., Borlaug, B. A., & Velazquez, E. J.
Venue
ESC Heart Failure
Published
2018-08-17
Volume
5
Issue
6
Pages
1035-1043
ISSN
2055-5822 (ISSN-L)
OpenAlex
W2886598107
Cited by
45
References
12
FWCI
2.92
Type
journal article
Language
en
Open access
gold
Funders
National Heart, Lung, and Blood Institute (U10 HL110338, U10 HL110336, U10 HL110309, U10 HL110302, U10 HL110297, U10 HL110262, U10 HL110342, U10 HL110337, U10 HL110312, U01 HL084861, U10 HL084904)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial. https://app.cochat.ai/papers/10.1002/ehf2.12334
The paper
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., Vader, J., Groake, J. D., Borlaug, B. A., & Velazquez, E. J. (2018). Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.12334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.